The information of our products contained in this section is partial and for orientation purposes only. A health care professional or certified physician must always be consulted for an appropriate diagnosis and use of these medications.
BRAND DRUG SUBSTANCE PRESENTATION
Patients currently controlled with therapeutic doses equivalent of acetylsalicylic acid, simvastatin and ramipril can switch directly to Trinomia capsules. The dose has to be individualized according to patient´s profile and blood pressure control. For cardiovascular prevention, ramipril maintenance dose is 10 mg once daily.
Trinomia is contraindicated in children and adolescents under 18 years.
Patients with renal impairment: Daily dose in patients with renal impairment should be based on creatinine clearance: ≥ 60 mL/min, the maximum daily dose of ramipril is 10 mg. - 30-60 m /min, the maximum dose is 5 mg ramipril. In patients with severe renal impairment (creatinine clearance <30 mL /min), Trinomia is contraindicated. Hepatic impairment: the maximum daily dose is 2.5 mg ramipril. In patients with severe hepatic impairment, Trinomia is contraindicated. Elderly: In very elderly and frail patients, treatment should be initiated with caution by an increased risk of side effects.
Trinomia hard capsules are administered orally with liquid, preferably in the evening after dinner. Trinomia should be swallowed with liquid, should not be opened, chewed or crushed. Avoid drinking grapefruit juice when taking Trinomia.
Note: Products which are still under patent are manufactured according to Argentinean requirements. Please note that they are delivered only to countries where the substance and its use are not protected by patents.